key: cord-0495140-bdlviexb
authors: Li, Jie; Zhang, Oufan; Kearns, Fiona L.; Haghighatlari, Mojtaba; Parks, Conor; Guan, Xingyi; Leven, Itai; Amaro, Rommie E.; Head-Gordon, Teresa
title: Reinforcement Learning with Real-time Docking of 3D Structures to Cover Chemical Space: Mining for Potent SARS-CoV-2 Main Protease Inhibitors
date: 2021-10-05
journal: nan
DOI: nan
sha: 64a3ef25687e38dc10cf4d72bb0c263df6139a92
doc_id: 495140
cord_uid: bdlviexb

We propose a novel framework that generates new inhibitor molecules for target proteins by combining deep reinforcement learning (RL) with real-time molecular docking on 3-dimensional structures. We illustrate the inhibitor mining (iMiner) approach on the main protease (MPro) protein of SARS-COV-2 that is further validated via consensus of two different docking software, as well as for druglikeness and ease of synthesis. Ultimately 54 molecules are proposed as potent Mpro inhibitors (7 of which have better synthetic accessibility), covering a much broader range than crowd-sourced projects like the COVID moonshot, and our generated molecules exhibit an optimized, precise, and energetically consistent fit within the catalytic binding pocket. Moreover, our approach only relies on the structure of the target protein, which means it can be easily adapted for future development of other inhibitors of any protein of disease origin.

The COVID-19 pandemic, caused by the spread and infection by a novel betacoronavirus called SARS-CoV-2, has brought immense loss to our global society, causing more than 232 million infection cases and more than 4.7 million deaths globally as of the end of September, 2021. 1 Even though effective vaccines have been developed, 2 numerous infected patients can still benefit from an effective antivirus drug targeting SARS-COV-2. While drug repurposing has led to the identification of some drugs as potential treatments for COVID-19 (for example, remdesivir), these have been met with somewhat underwhelming performance in clinical settings. 3 Of course, drug re-purposing strategies also suffer the distinct limitation in that they cannot identify novel molecules that would be highly potent for new targets.

Among all the proteins related to the SARS-COV-2 virus, Mpro has arguably received the most attention with respect to drug re-purposing studies, 4 in part because it is one of the earliest SARS-COV-2 proteins in which the 3d structure has been fully determined experimentally. 5 It is also an attractive target due to its crucial role in the SARS-CoV-2 replication cycle since it is a critical enzyme facilitating the cleavage of non-structural proteins from two polyproteins translated from the SARS-CoV-2 replicase gene (Orf1). 6, 7 The substrate-binding pocket of Mpro is located at a cleft between Domain I (residues 8-101) and Domain II (residues 102-184) of the protein, with a Cys-His catalytic dyad that catalyses the cleavage of the polyprotein 1ab. 5, 8 Molecules inhibiting Mpro can induce a conformational change of the protein which leads to its aggregration, 9 or occupy the core 2 of the substrate-binding pocket, blocking substrates from approaching the catalytic site. 10 Besides its crucial biological function for virus viability, Mpro is also a promising target for drug development because it is a cytosolic protein with better accessibility to ingested antivirals, and has a well-defined concave binding pocket that allows for more consistent design of small molecules. 11 Furthermore, the cleavage sites Mpro operates at do not have known overlap with human proteases. 8, 12 Therefore, an inhibitor targeting Mpro is unlikely to be toxic to humans.

Traditional methods for identifying specific small molecule inhibitors of a protein target usually start with high throughput virtual screening of massive databases that attempt to capture chemical space and diversity, e.g., ChEMBL, 13 ZINC, 14 Enamine Diversity Set, 15 and PubChem. 16 Due to the size of such data sets, screening these molecules with sophisticated flexbile ligand docking protocols can become intractably expensive. Thus, less sophisticated methods, such as pharmacophore modeling or rigid body docking, are often used to initially screen molecules. Due to the simplicity of these models, the information used to navigate through the small molecule chemical space becomes noisy, and false-positives are ruled in while false-negatives, i.e. potential optimum lead molecules, can be ruled out. 17, 18 With the advent of modern machine learning, deep learning models have been proposed that can generate new molecules for SARS-COV-2 and other viral diseases, 19-29 and the distribution can be skewed towards molecules with specific properties such as drug likeness using techniques such as variational autoencoders (VAE), 20,21 transfer learning 22 and reinforcement learning (RL). [23] [24] [25] [26] [27] [28] [29] However, most deep learning methods rely on 1-dimensional sequence or 2-dimensional chemical representations of the drug and protein, and do not take full advantage of 3-dimensional structural information of the putative drug, thereby constraining the ability to generate drugs with shape and molecular compatibility with the target active site. Recent work has also explored chemical space in the vicinity of some starting molecular scaffold and running docking simulations on these derived molecules, 30 however there has been no method that develops new drug molecules with real-time 3d struc-tural docking to guide the efficient exploration of an immense chemical space with the aid of machine learning.

In this work, we propose a novel workflow dubbed "iMiner" that mines chemical space for new tight binding inhibitors by combining deep RL with real-time flexible ligand docking against a protein binding site ( Figure 1 ). We represent putative inhibitors as Self-Referencing Embedded Strings (SELFIES) 31 that are generated from an Average Stochastic Gradient Descent Weigh-Dropped Long Short Term Memory (AWD-LSTM) 32 recurrent neural network (RNN), allowing wide coverage of chemical space. We illustrate the RL training procedure of iMiner that uses on-the-fly AutoDock Vina 33 with the 3d structures of the Mpro substrate binding pocket and the generated inhibitors. The Vina docking scores are used to adjust the RNN so that the distribution of generated inhibitor molecules are shifted towards those that more strongly interact with the Mpro catalytic site. We perform docking with a second docking software, Schrödinger's Glide SP, 34 to build consensus for a drug's strong binding affinity to Mpro, and a final filtering based on synthetic accessibility (SA), druglikeness, and elimination of PAINS 35 molecules.

In our Covid-19 relevant example, we propose 54 molecules as potential Mpro inhibitors that are worthy of experimental validation (work in progress). 7 out of the 54 molecules have even better synthetic accessibility. Furthermore, we compare our top hits generated with the iMiner workflow with the molecules submitted to the COVID moonshot project, 36 a crowdsourcing effort aimed at developing a novel inhibitor for Mpro, and show that we achieve a broader coverage of the inhibitor drug chemical space. We also find excellent shape and molecular attributes of the inhibitors generated by our model in regard their compatibility with the actual target cavity in Mpro, which is a direct consequence of the real-time docking with actual 3d structures during the training procedure. Further analysis of non-bonded interactions between the found inhibitors with specific binding pocket residues in Mpro also create testable hypotheses in regards their potential role as antivirals to treat COVID-19. 4 Although we have illustrated the workflow's first use on a pressing and timely test case -i.e., inhibition of SARS-CoV-2 Mpro due to the desperate need for antiviral treatments of COVID-19 -the iMiner method is highly generalizable. As our workflow only requires a 3D structure of the target protein with a pre-defined binding site, iMiner can be readily adapted to generate small molecules for other protein targets. Thus, we believe our ML algorithm will be of great interest to the drug design community to rapidly screen novel regions of chemical space in real-time for other anti-virals or small molecule therapeutics in the future.

All scripts required to run our workflow on an arbitrary protein target can be found on a public GitHub repository 1 . SELFIES representation of inhibitor molecules. An arbitrary molecule can be represented as a topological graph using two main approaches: adjacency matrix based methods and string based methods. The former uses an N by N matrix to encode a molecule, where N is the number of atoms in the molecule, and the values of the matrix are typically bond orders between atoms. An adjacency matrix is not ideal for generative tasks, because the size of the molecule that can be generated should not be fixed, and the learning of chemical knowledge by a ML model through adjacency matrix can be difficult. Instead, string based methods are more suited for molecular generation tasks, and SMILES strings have been the standard for molecular representation due to its conciseness and readability.

However, SMILES strings have relatively complex syntax, require matching of open and close brackets for branching, and ring modeling/modification is not trivial. Therefore, generating novel, chemically correct compounds through use of SMILES strings can be challenging.

The SELFIES molecular representation 31 is specifically designed to ensure that all gen-1 https://github.com/THGLab/Covid19 Figure 1 : Illustration of the overall structure of the iMiner workflow which highlights the two major machine learning components, the generative and evaluative models and their interplay, and the subsequent filtering process for chemical and biological feasibility. with predefined branch lengths and ring sizes, as well as generating symbols using derivation rules, the SELFIES representation guarantees that valence bond constraints are met, and any combinations of tokens from its vocabulary corresponds to a valid molecule. Therefore, we have used SELFIES in our generative model to encode molecules since it does not need to learn chemical syntax rules, and can allocate more of its learning capacity towards generating valid molecules with properties of interest as shown in Figure 1A .

Pre-training the inhibitor molecule generation. Conceptually, generating molecules using string representation is similar to how text is generated in a natural language process-6 ing task. Our method starts with a specific [Break] token, and for each molecule, we utilized an RNN that takes in the last token in the string, together with the hidden state from last step to predict a distribution of tokens following the current string. In this work a specific variant of the RNN, known as the AWD-LSTM, was used due to its exceptional performance in similar generative tasks ( Figure 1A ). 32 The network was pre-trained using supervised-learning (SL) of all molecules from the ChEMBL database to learn the conditional probability distributions of tokens that correspond to drug-like molecules. When our trained generative model is used for generating new molecules, a new token is sampled according to the predicted probabilities, and this new token is concatenated to the input string to sample the next token, until the [Break] token is sampled, in which case a complete molecule has been generated.

The performance of our pre-trained generative model was evaluated using the GuacaMol benchmarks, 37 which probe 5 different aspects of the distribution of generated molecules with respect to the training dataset (Table 1) . Model "validity" reports the proportion of molecules that are syntactically correct. Because we generated molecules via SELFIES representations, we achieved close to 100% validity for all generated molecules. Invalid molecules were either empty strings, or molecules for which the SELFIES package failed to convert into a SMILES string and therefore were discarded before subsequent workflow steps.

Model "uniqueness" reports how many generated molecules are duplicates vs. those which are genuinely distinct. Our pretrained models illustrated high uniqueness, indicating the model is able to generate a wide variety of non-redundant molecules. Model "novelty" is defined as the proportion of generated molecules that do not exist in the training dataset. Our model's high novelty indicates that it is not memorizing molecules from the training dataset, but is indeed generating molecules that it has not seen before. Kullback-Leibler (KL) divergence measures differences in probability distributions of various physicochemical descriptors for the training set and the model generated molecules. As defined by GuacaMol, a high KL divergence benchmark such as predicted for our model suggests that our generated molecules 7 have similar physicochemical properties to that of training dataset. Finally, Frechet ChemNet Distance (FCD) utilizes a hidden representation of molecules in a previously trained NN to predict biological activities, and thus captures both chemical and biological similarities simultaneously for two sets of molecules. 38 Molecules generated by our pre-trained model also have high FCD values, indicating that our molecules are expected to have similar biological activities as molecules from the ChEMBL training dataset. We then validated our pre-trained distributions using 13 drug-likeliness properties between our generated molecules and randomly sampled molecules from ChEMBL database 41 Despite the fact that during pre-training only token distributions were used as training targets, all distributions collected from our generated molecules closely follow the distributions from the ChEMBL database ( Figure S1 ). This result suggests our pre-trained model has learned key concepts of "drug-likeness" and provides a good starting point for the RL procedure.

The evaluation module. After our generative model was pre-trained, we employed 8 an RL workflow to bias the distribution of generated molecules towards specific properties of interest. RL training allows the model to interact with an environment by performing actions according to a policy model, and uses the feedback from the environment to provide training signals to improve the model. In this work, the pre-trained generative model is taken as the policy, and in each iteration 2000 molecules were generated and sent to the evaluation module ( Figure 1A ). proximal policy optimization (PPO), 42 as will be discussed in next section. We emphasize that by using a physics-based docking model which utilizes full 3D structure of our target protein and generated molecules as the critic, the training of the policy model is less likely to be contaminated due to exploiting failure modes of a neural-network based critic, an issue called wireheading. 43 Instead, we benefit from a more reliable training signal and reduce the false positive and false negative rates of the generated molecules.

Vina scores alone are not sufficient to reliably train a molecule generator, as shown in the Supporting Information ( Figure S2 ) because it will not always satisfy requirements for drug-likeness. To ensure that our generated molecules still bear drug-like properties, we incorporated an additional metric into the reward, S DL , which is a weighted average of the log likelihood for the 13 different drug-like properties used in pre-training assessment.

9

Formally, our drug-likeliness score S DL is defined as:

where prop i (X) calculates the ith property of a molecule X and p i is defined by the probability distribution of property i by all molecules in the ChEMBL database. The parameter σ i is defined as:

where S i is the entropy of the distribution of property i,

such that a narrower distribution from the ChEMBL database contribute more to the drug likeliness score, and defines the weights for each property as proportional to the inverse of the entropy. Introducing this additional reward ensures our model also accounts for similarity of generated molecules to the drug-likeliness present in the ChEMBL database, and ensures that our generated molecules are more likely to be optimal leads for further drug design endeavors.

Reinforcement learning with multiple rewards. Our pretrained policy model defines a probability distribution for an arbitrary sequence of tokens from the SELFIES vocabulary, since the generation of the sequence is a Markovian decision process (MDP), and can be written as: 

since the drug-likeliness score needs to be maximized and Vina score needs to be minimized.

The λ parameter controls the balance between the physical Vina score and the drug-likeliness score in the reward function, but in this work we simply used λ = 1. Negative S DL is upward clipped to 0 and positive S vina is downward clipped to 0 to ensure the reward is non-negative.

The expected reward under the MDP is then

Further details of the RL training procedure are given in the Methods section. the generated molecules, and they are still similar to the structures from ChEMBL database.

However, FCD has changed significantly, which means the newly generated molecules have different biological activities than the molecules from ChEMBL database. The changes seen in FCD are expected, since, after training, the generated molecules should target a specific cavity of SARS-CoV-2 Mpro, a target for which there are currently no FDA approved treatments. Thus, the FCD differences validate that RL is properly steering the distributions of generated molecules away from its initial distribution.

Validation and filtering of new inhibitor molecules. Validating results from, or checking for consensus between, one docking program with another is often considered standard practice as scoring functions from different programs may have limited accuracy or be parameterized for differing test cases. 44 Furthermore it is desirable to filter out molecules that are non-specific binders (Pan-assay interference compounds or PAINS) in which we use swissADME 45 to check for any PAINS alerts, 35 as well as Lipinski rule violations, 46 and to evaluate the synthetic accessibility (SA) scores of these molecules. Figure 1B illustrates the procedures for post-filtering using these additional metrics, which we describe in more detail here.

We start by collecting all molecules from intermediate RL training iterations with a Vina score <-9.0, arriving at our "vina-selected set" containing 33,105 molecules (the number of molecules from each training iteration is provided in Figure S3 ). As expected, more molecules from later iterations were selected, since molecules from later iterations were driven towards having lower Vina scores. Glide Standard Precision (SP) 34 docking was performed on all molecules in our vina-selected set with the flexibility to optimize the conformation again with respect to the Glide scoring function. This way we could fully exploit Glide docking as a cross-validation for the generated molecules. Even though the molecules were all good candidates according to Vina score, their glide docking score still showed a wide distribution.

We then applied a filter with Glide Gscore (Glide Score) <-8.0 and a drug-likeliness score filter of >2.7 to exclude any structure that is not sufficiently drug-like. After applying these filters we obtained the glide-selected set with 321 molecules in total. The final step was to run these 321 molecules through a final set of filters requiring no PAINS alerts, no Lipinski rule violations and SA scores <3.5.

The outcome of the iMiner workflow formulated a final set of 54 molecules shown in Figure   3 . These molecules are predicted to be consensus Mpro inhibitors by both AutoDock Vina and Glide SP, they satisfy drug-likeliness criterion, and are relatively easy to synthesize due to their predicted low SA scores. The full SMILES representations of these molecules, along with their Vina scores, Glide Gscores, and SA scores are provided in Table S1 .

Comparison of chemical diversity of inhibitors discovered by iMiner. We propose further experimental validations on these molecules as potential SARS-CoV-2 Mpro inhibitors (work in progress). The first 7 molecules in the dashed frame have better synthetic accessibility scores than the rest. The diversity over chemical space of these proposed inhibitors is evident from metrics described in Table 1 and Figure 4 . Although identifying antiviral treatments for SARS-CoV-2 is of pressing concern at the time of this publication, our model could be quickly applied to design novel inhibitors for proteins relevant to other global diseases. For example, bacterial resistance to antibiotics is of preeminent concern in the medical community, 53 and our iMiner workflow approach could be used to target novel bacterial biomolecules, such as bacterial Ribosomes, or target resistance conferring bacterial proteins such as β-lactamase. 53 Overall, we believe our tool will be of great benefit to the computational and medicinal chemistry fields at large, and potentially aid traditional drug-design workflows as well. For example, molecules that are experimentally validated through a traditional HTVS approach as good binders could utilize the iMiner algorithm as an optimization or refinement step for elaborating on these existing leads or scaffolds. The potential of the method in this direction will be explored in future work. Supervised pretraining of the network The generative model was pretrained using molecules from ChEMBL 24, 13 and a total of 1,440,263 molecules were selected for training.

All molecules were first converted to SELFIES strings using the selfies python package, 31 and the tokens were extracted from the SELFIES strings with fastai language model. We used categorical cross entropy loss:

where N represents the number of tokens in a molecule,p(t i |t 1 , t 2 , ..., t i−1 ) represents the actual probability of a specific token in the string at position i and with all previous defined tokens t 1 through t i−1 , and p Θ (t i |t 1 , t 2 , ..., t i−1 ) the probability predicted by the neural network with parameters Θ. The model was trained using Adam optimizer 58 in batches of size 512, and we employed the "one cycle" learning rate policy 59 with the maximum learning rate 21 of 0.0005 to achieve superconvergence. 60 During this pretraining stage we also used weight decay=0.01 and the dropout multiplier of 0.2. The model was pretrained for 30 epochs.

Reinforcement learning procedure. Our RL training target goal is to maximize J(Θ) from formula(6) by taking steps along ∂ Θ J(Θ). The exact value for J(Θ) is intractable to evaluate, but can be approximated through sampling the distribution of s T , which gives

and then

Directly taking gradients according to (16) corresponds to the REINFORCE algorithm. 61 In this work we further utilized the PPO algorithm, 42 which estimated the gradients through a clipped reward and with an extra entropy bonus term:

where

denoting the ratio between the probability distribution in the current iteration and the prob-ability distribution from the previous iteration (the iteration before last gradient update). A PPO algorithm reduces variance in the gradient, stabilizes training runs, and also encourages the model to explore a wider region of the chemical space through the introduction of an entropy bonus term. The two hyperparameters in the algorithm, α and , were taken as α = 0.02, = 0.1 in this work.

After the pretraining finished, we copied the weights to a separate model with identical architecture and trained with reinforcement learning using PPO. In each iteration 2000 molecules were sampled, and model weights were updated by taking gradient steps on the target function through formula (17) 

Methodology details, supporting table S1, supporting figures S1-S4. • Modifier tokens: ["H+expl", "H2+expl","H3+expl","+expl","Hexpl","H2expl","H-expl","H2expl","H3-expl","-expl","expl"]

• Functional tokens: ["Break"]

When sampling molecules represented as SELFIES strings, the first token was always selected as the "Break" token. Then each token was sampled with probability distribution predicted by the generative model. Once the "Break" token was selected again, or the total number of tokens exceeded 500, a single molecule sampling process was considered complete. For each modifier token in the sampled string, it was combined into the previous token and was connected by the All docking input files and protein structures will be shared in conjunction the data sharing philosophy put forth by Rommie E. Amaro and Adrian Mulholland. ? . The molecular properties considered are well-recognized chemical features related to the drug-likeliness of a molecule which can be obtained through 2D topological connectivity of the molecule: fraction of sp 3 hybridized carbons(fracsp3), number of heavy atoms(heavy), fraction of non-carbon atoms in all heavy atoms(hetero), number of hydrogen bond donors(hbd) and acceptors(hba), number of rotatable bonds(rotb), number of aliphatic(alip) and aromatic rings(arom), molecular weight(mw), quantitative estimate of drug-likelihood (QED) value, ? approximate log partition coefficient between octanol and water (alogP), ? polarizable surface area (PSA), and the number of structural alerts(alerts). ? Figure S2 : Example molecules generated using reinforcement learning without utilizing the druglikeliness metric as additional reward. Many of these molecules are not drug-like, i.e. having large rings, or having a high proportion of hetero atoms. Figure S3 : Number of molecules selected into the vina-selected set from each RL training iteration 13 Figure S4 : Change of mean entropy of model-predicted token probabilities and mean Vina scores of generated molecules during the training process. The model after RL is the model at iteration 400, and any molecules generated after iteration 400 are not considered for subsequent analysis.

COVID-19) Dashboard -WHO Coronavirus

Dashboard With Vaccination Data

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Remdesivir in treatment of COVID-19: a systematic benefit-risk assessment

Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Conservation of substrate specificities among coronavirus main proteases

Coronaviruses: an overview of their replication and pathogenesis

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro

Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro

Design of wide-spectrum inhibitors targeting coronavirus main proteases

coronavirus structure

De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence

Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2

Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors

Self-referencing embedded strings (SELFIES): A 100representation

Regularizing and Optimizing LSTM Language Models

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes

PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS

COVID moonshot: open science discovery of SARS-CoV-2 main protease inhibitors by combining crowdsourcing, high-throughput experiments, computational simulations, and machine learning

GuacaMol: benchmarking models for de novo molecular design

Fréchet ChemNet distance: a metric for generative models for molecules in drug discovery

Quantifying the chemical beauty of drugs

Prediction of physicochemical parameters by atomic contributions

Lessons learnt from assembling screening libraries for drug discovery for neglected diseases

Proximal policy optimization algorithms

Avoiding wireheading with value reinforcement learning

Consensus docking: improving the reliability of docking in a virtual screening context

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Visualizing data using t-SNE

Principal component analysis. Chemometrics and intelligent laboratory systems

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)-A drug repurposing study

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN

The antibiotic resistance crisis: part 1: causes and threats. P & T : a peer-reviewed journal for formulary management

Acceleration of stochastic approximation by averaging

Regularization of neural networks using dropconnect. International conference on machine learning

Automatic differentiation in PyTorch

Fastai: a layered API for deep learning

A method for stochastic optimization

A disciplined approach to neural network hyper-parameters: Part 1-learning rate, batch size, momentum, and weight decay

Super-convergence: Very fast training of neural networks using large learning rates. Artificial Intelligence and Machine Learning for Multi-Domain Operations Applications

Simple statistical gradient-following algorithms for connectionist reinforcement learning

FC(c1ccc(cc1)S(=O)(=O)Nc1cccc(c1)OCc1ccc2c(n1)cccc2)(F)F

OC(=NCc1ccc(cn1)S(=O)(=O)c1ccc(nc1)C(F)(F)F)c1cnc2n(c1)

O=C(c1ccc2c(c1)cccc2)NCc1ccc(cc1)S(=O)(=O)c1cccc(c1)

O=C(c1cccs1)NN=Cc1ccc(cc1)OCc1ccc(cc1)

Fc1ccc(cc1)c1cncc(c1)C(=O)N1CC(C1)Oc1ccc2c(c1)c1cnccc1

Fc1cnc(nc1c1cnc2c(c1)cccc2)Nc1cc(C)c(c(c1)c1[nH]cnn1)F

Fc1ccc(cc1)N1CCN(CC1)C(=O)Nc1nonc1NC(=O)c1ccc(cc1)F

O=S(=O)(c1cccc(c1)C(F)(F)F)Nc1cccc(c1)c1ccc(nn1)

Fc1ccc(cc1)c1n[nH]c2c1cc(cc2)NS(=O)(=O)c1cccc(c1)c1ccc

O=c1c2cccc3c2n(c2c1cccc2)sc3NS(=O)(=O)C=Cc1ccccc1

O=S(=O)(c1cccc(c1)C(F)(F)F)Nc1cccc(c1)c1ccc(nc1)

Oc1cccc(c1)c1cccc(c1)S(=O)(=O)Nc1ccc(cc1)c1cccc(c1)c1nnn

O=C1NCc2c(C1)ccc(c2)S(=O)(=O)c1cn(nc1c1ccc(cc1F)F)

O=C1Cc2c(N1)cc(cc2)c1cccc2c1ccc(c2)NS(=O)(=O)c1cccc(c1)C(F)(F)F

Fc1ccc(cc1)C(=O)Nc1cccc(c1)C(Nc1ncnc2c1cccc2C(=O)N)C

Fc1ccn2c(c1)ncc2c1cc(ccc1F)NS(=O)(=O)c1cccc(c1)

O=S(=O)(c1cccc2c1cccc2)Nc1cc(c2n1cccc2)c1ccc2c(c1)

O=S(=O)(c1ccc(cc1)Oc1cccc(c1)c1cc2c([nH]1)cccc2)Nc1ncn

=O)(=O)Nc1ccc2c(c1)c(n[nH]2)c1nc2c

Fc1ccc(cc1)S(=O)(=O)c1ccc(cc1)NS(=O)(=O)c1ncnc(c1)

)ccc(c2)S(=O)(=O)

Oc1ccc2c(c1)cc(o2)c1cccc(c1)S(=O)(=O)c1nc2c(s1)

O=S(=O)(c1ccccc1)N(Cc1cccnc1)Cc1ccc(cc1)Oc1ccc(cc1)c1

O=S(=O)(c1cccc(c1)c1ccncc1)c1cccc(c1)C=Nc1nc2c([nH]1)cccc2

Fc1ccc(cc1)S(=O)(=O)c1ccc(cc1)NS(=O)(=O)c1ncnc(c1)

Oc1cccc(c1)C=Nc1cccc(c1)NS(=O)(=O)c1cccc(c1)

O=S(=O)(N1CCc2c(C1)nc(nc2)Nc1ccccc1)c1ccc(cc1)

O=S(=O)(c1cccc(c1)c1ccccc1)Nc1cccc(c1)c1ncc2c(c1)

Oc1cccc(c1)Nc1nc2c([nH]1)ccc(c2)S(=O)(=O)c1cccc(c1)

O=S(=O)(c1cccc(c1)c1cnc2n1ccnc2)c1ccc(cc1)

Fc1cnc2c(c1)ncn2c1cccc(c1)S(=O)(=O)c1nc2c(s1)cc(cc2)

Oc1nccn1c1ccc2c(c1)cccc2NS(=O)(=O)c1cccc(c1)

O=S(=O)(Oc1n[nH]c(c1)c1ccccc1)Oc1cccc(c1)

O=S(=O)(c1ccc2c(c1)cccc2)Nc1cccc(c1)c1coc(n1)

O=S(=O)(c1cccc(c1)c1ccccc1)c1ccc(cc1)Nc1ncc2c(c1)

O=S(=O)(c1cccc(c1)c1ccccc1)Nc1ccc2c(c1)cc(cc2)S(=O)(=O)N

Fc1ccc2c(n1)ncc(c2O)Cc1ccc(cc1)S(=O)(=O)c1ccc2c(n1)

O=S(=O)(c1cccc(c1)c1ccccc1)Nc1cc2c(c1)

Fc1ccc(cc1OS(=O)(=O)c1ccc2c(c1)[nH]cc2)c1cccc(c1)

Oc1nn(O)[nH]c(c1)c1cccc(c1)S(=O)(=O)c1cccc(c1)

Fc1ccc(cc1NS(=O)(=O)c1cccc(c1)c1cccnc1)c1[nH]c2c(n1)

Oc1ncc(cc1c1cccc(c1)S(=O)(=O)c1cccc(c1)c1ccccc1)c1ccncc1